| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2018-04-16 |
| タイトル |
|
|
タイトル |
Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: A retrospective cohort study |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.24517/00050515 |
|
ID登録タイプ |
JaLC |
| 著者 |
Hayashi, Tomoyuki
Yamashita, Taro
Terashima, Takeshi
Suda, Tsuyoshi
Okada, Hikari
Asahina, Yoshiro
Hayashi, Takehiro
Hara, Yasumasa
Nio, Kouki
Sunagozaka, Hajime
Takatori, Hajime
Arai, Kuniaki
Yamashita, Tatsuya
Mizukoshi, Eishiro
Honda, Masao
Kaneko, Shuichi
|
| 著者別表示 |
林, 智之
山下, 太郎
寺島, 健志
須田, 烈史
岡田, 光
朝日向, 良朗
丹尾, 幸樹
砂子阪, 肇
鷹取, 元
荒井, 邦明
山下, 竜也
水腰, 英四郎
本多, 政夫
金子, 周一
|
| 提供者所属 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
金沢大学先進予防医学研究科 |
| 書誌情報 |
BMC Cancer
巻 17,
号 1,
p. 870,
発行日 2017-12-19
|
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1186/s12885-017-3889-x |
| 出版者 |
|
|
出版者 |
BioMed Central Ltd. |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Sorafenib is a multiple receptor tyrosine kinase inhibitor known to prolong overall survival in patients with advanced hepatocellular carcinoma (HCC). Predicting this drug's survival benefits is challenging because clinical responses are rarely measurable during treatment. In this study, we hypothesized that serum cytokines levels could predict the survival of advanced HCC patients, as sorafenib targets signaling pathways activated in the tumor stromal microenvironment and potentially affects serum cytokine profiles. Methods: Of 143 patients with advanced-stage HCC, 104 who were recruited between 2003 and 2007 received hepatic arterial infusion chemotherapy (HAIC) that mainly targets tumor epithelial cells at S-phase (cohort 1); additionally, 39 recruited between 2010 and 2012 received sorafenib, which primarily targets the stromal vascular endothelial cells. Serum samples were collected and aliquoted prior to the treatment. Serum EGF, bFGF, HGF, IFN-γ, IL-10, IL-12, IL-2, IL-4, IL-5, IL-6, IL-8, IP-10, MIG, PDGF-BB, SCF, SDF1, TGF-β, TGF-α, TNF-α, and VEGF-A were measured via enzyme-linked immunosorbent assays. The Modified Response Evaluation Criteria in Solid Tumors were used to assess tumor responses. Results: The median survival time of HCC patients in cohorts 1 (HAIC-treated) and 2 (sorafenib-treated) were 12.0 and 12.4 months, respectively. Kaplan-Meier analysis revealed no significant survival differences between the 2 groups. Patients who survived more than 2 years after sorafenib treatment exhibited higher serum levels of IL-10, IL-12, TNF-a, IL-8, SDF-1, EGF, PDGF-BB, SCF, and TGF-α. Furthermore, cohort 2 patients with higher serum IL-5 (>12 pg/mL), IL-8 (>10 pg/mL), PDGF-BB (>300 pg/mL), and VEGF-A (>50 pg/mL) levels achieved longer survival; cohort 1 patients did not. Hierarchical cluster analysis of 6 cytokines robustly enriched for comparison analysis between cohorts 1 and 2 (IL-5, IL-8, TGF-α, PDGF-BB, CXCL9, and VEGF-A) revealed that elevation of these cytokines correlated with better survival when treated with sorafenib but not with HAIC. Conclusions: Patients who exhibited survival benefits owing to sorafenib treatment tended to present higher serum cytokines levels, potentially reflecting the activation of stromal signaling in the tumor microenvironment. Our study thus introduces novel biomarkers that may identify advanced HCC patients who may experience survival benefits with sorafenib treatment. © 2017 The Author(s). |
| 権利 |
|
|
権利情報 |
Copyright © 2017 The Author(s) / BioMed Central Ltd. |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
ME-PR-HAYASHI-T-870.pdf (861.6 kB)
.png)
